Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Arun Azad, PhD, MBBS, FRACP
Advertisement
Articles by Arun Azad, PhD, MBBS, FRACP
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
ESMO 2025: The Top 10 Takeaways That May Shift Oncology Practice
2
ctDNA Status May Determine Adjuvant Immunotherapy Benefit in MIBC
3
Frontline Tislelizumab Combo Improves Long-Term Survival in ES-SCLC
4
FDA Approves Revumenib in R/R NPM1-Mutant AML
5
